This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.
Compared to Estimates, ResMed (RMD) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ResMed (RMD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of +2.41% and +0.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to ResMed (RMD) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Do Options Traders Know Something About ResMed Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GEHC Stock Up Following Approval to Boost Hemodynamic Monitoring
by Zacks Equity Research
GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
by Zacks Equity Research
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
Zacks.com featured highlights include Stryker, NVIDIA, ResMed and Ralph Lauren
by Zacks Equity Research
Zacks highlights four GARP (Growth at a Reasonable Price) stocks Stryker, NVIDIA, ResMed, and Ralph Lauren combining strong growth prospects with attractive valuations for maximum returns.
Here's Why ResMed (RMD) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top Analyst Reports for Home Depot, Boeing & Progressive
by Mark Vickery
Analysts spotlight Home Depot, Boeing, and Progressive in today's top Zacks reports, revealing growth drivers, risks, and key performance trends.
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
by Vasundhara Sawalka
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
GEHC Stock Up Following New Launch to Streamline Perinatal Workflow
by Zacks Equity Research
GE HealthCare unveils CareIntellect for Perinatal, a SaaS tool aimed at improving maternal and fetal care delivery.
Abbott (ABT) Q3 Earnings Meet Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and -0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BD Stock Down Despite Making Progress in the Treatment of PAD Lesions
by Zacks Equity Research
BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.
Zacks.com featured highlights include ResMed, Safran, Pentair, Casey's and Leonardo
by Zacks Equity Research
Amid market uncertainty, low-leverage stocks RMD, SAFRY, PNR, CASY, and DRS emerge as safer investment options for steady growth.
BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow
by Zacks Equity Research
BDX teams with Opentrons to automate single-cell sequencing, advancing its multiomics and biosciences strategy.
5 Low-Leverage Stocks to Buy as Market Takes a Tumble
by Aparajita Dutta
As markets tumble, low-leverage stocks like RMD, SAFRY, PNR, CASY, and DRS offer safer investment options for steady returns.
Neogen (NEOG) Q1 Earnings Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -20.00% and +2.96%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
by Zacks Equity Research
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nyxoah Expands in the Middle East to Provide Wider Access to Genio
by Zacks Equity Research
NYXH expands in the Middle East after Abu Dhabi's first Genio implant, aiming to broaden access for OSA patients.
Zacks.com featured highlights include GE Aerospace, ResMed, Vertiv and National Fuel Gas
by Zacks Equity Research
GE Aerospace, ResMed, Vertiv, and National Fuel Gas emerge as Zacks GARP picks, blending growth prospects with value appeal.
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, RMD, VRT and NFG are some such stocks.
Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring
by Zacks Equity Research
BAX launches FDA-cleared Connex 360 monitor, aiming to boost frontline care and streamline patient monitoring.